Navigation Links
Royalty Pharma Announces Offer May Lapse (Be Withdrawn)
Date:6/13/2013

are intended to identify forward looking statements but are not the exclusive means of identifying such statements. By their nature, forward looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur.

Examples of such forward looking statements include (but are not limited to) statements about expected benefits and risks associated with the Further Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. PDL BioPharma Provides Second Quarter 2013 Royalty Revenue Guidance of $143 Million
2. Royalty Pharma Files Judicial Review Proceedings
3. Royalty Pharma Posts Investor Presentation Summarizing Further Increased Offer For Elan
4. Royalty Pharma Statement Regarding Withdrawal of Elan Lawsuit
5. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
6. Royalty Pharma Acceptances Announcement
7. Royalty Pharma Responds To Elans Tysabri Valuation
8. Royalty Pharma Response To Elans "Categorical View On Value"
9. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... Oct. 17, 2014 Research and ... "Research and Development Prospect of China Dialysis Market, ... Based on the 2013 version, this update ... about dialysis industry and the relevant effect in ... dialysis industry segmentations. Moreover, it analyzes Chinese private-owned ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... WAILEA, Hawaii and SUNNYVALE, Calif., June 27, ... from two open-label, multi-center Phase 2,clinical trials ... Injection, the company's lead product,candidate, in combination ... (docetaxel) as a second-line treatment,for patients with ...
... WIRE)--Jun 27, 2007 - Columbia,Laboratories, Inc. (NASDAQ: ... multi-dose pharmacokinetic study of,vaginally-administered lidocaine, which the ... This 42-subject study was designed to provide ... bioadhesive vaginal lidocaine,formulation at three dose strengths ...
Cached Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 2Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 3
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... that the public will use performance data to choose their ... a paper published on bmj.com today, two experts ... choice is not at present a strong lever for change, ... improved to optimise its effect. Research conducted over the ...
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... of heartburn drugs while they were pregnant did not ... a large Danish study finds. This class of ... as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole). All ...
... 24 (HealthDay News) -- Excessive alcohol consumption -- a common ... injury and death, warns the American College of Emergency Physicians ... when they get together with family and friends. "Very ... suffer the loss of a loved one because of an ...
... , WEDNESDAY, Nov. 24 (HealthDay News) -- Parents ... if they,re traveling during the holiday season, an expert warns. ... you can,t plan for everything, being prepared will help keep ... Cahill, an associate professor of pediatrics at Loyola University Chicago ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... Americans get ready to travel to holiday gatherings with family and ... them are reminded that there are some things you need to ... pack a copy of all vaccination records so that you can ... those records if you board your pet while going on an ...
Cached Medicine News:Health News:Experts question whether patients will use performance data to choose their care 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Holiday Drinking Can Kill, Experts Warn 2Health News:Preparation Can Help Kids With Nut Allergies Travel Safely 2Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2
Claes Shielded Retinotomy Scissors, Vertical...
... DxSelect is intended for qualitatively detecting antibodies ... serum. The test is indicated for testing ... an aid in the presumptive laboratory diagnosis ... intended for self-testing, and this test is ...
... Indirect immunofluorescent antibody (IFA) test for ... IgG antibodies to St. Louis Encephalitis virus ... Equine Encephalitis virus (EEE), and California Encephalitis/La ... 8-well slides with fixed individual spots of ...
... immunofluorescent antibody (IFA) test ... semi-quantitation of human serum ... viral capsid antigen (VCA). ... 12-well slides, FITC IgG ...
Medicine Products: